Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 10/20 | 0.46 |
| ▸ | THRA | P10827 | 8/20 | 0.46 |
| ▸ | RORC | P51449 | 3/20 | 0.43 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16496217 | 1.00 | THRB (0.46) | THRBTHRARORCTNFRSF1AMAPK1 | |
| SCHEMBL2170982 | 0.93 | TNFRSF1A (0.41) | THRBTHRATNFRSF1AMAPK1HSD17B10 | |
| SCHEMBL16495878 | 0.93 | TNFRSF1A (0.41) | THRBTHRATNFRSF1AMAPK1HSD17B10 | |
| SCHEMBL2171186 | 0.92 | THRB (0.44) | THRBTHRARORCTNFRSF1AMAPK1 | |
| SCHEMBL16495821 | 0.92 | THRB (0.44) | THRBTHRARORCTNFRSF1AMAPK1 | |
| SCHEMBL2170701 | 0.89 | TNFRSF1A (0.40) | TNFRSF1AMAPK1HSD17B10LMNAMAPT | |
| SCHEMBL2170699 | 0.89 | TNFRSF1A (0.40) | TNFRSF1AMAPK1HSD17B10LMNAMAPT | |
| SCHEMBL16496195 | 0.89 | RORC (0.55) | THRBTHRARORC | |
| SCHEMBL2170227 | 0.89 | RORC (0.55) | THRBTHRARORC | |
| SCHEMBL16496152 | 0.88 | THRB (0.46) | THRBTHRARORCTNFRSF1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301200-A1 | THYROID RECEPTOR LIGANDS | CADILA HEALTHCARE LIMITED (IN) | 2011-12-08 | — | — | US | claimed |
| EP-2346814-A2 | THYROID RECEPTOR LIGANDS | Cadila Healthcare Limited (IN) | 2011-07-27 | — | — | EP | claimed |
| WO-2010049946-A2 | THYROID RECEPTOR LIGANDS | CADILA HEALTHCARE LIMITED (IN) | 2010-05-06 | — | — | WO | claimed |
| US-20110301200-A1 | THYROID RECEPTOR LIGANDS | CADILA HEALTHCARE LIMITED (IN) | 2011-12-08 | — | — | US | disclosed |
| EP-2346814-A2 | THYROID RECEPTOR LIGANDS | Cadila Healthcare Limited (IN) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010049946-A2 | THYROID RECEPTOR LIGANDS | CADILA HEALTHCARE LIMITED (IN) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301200-A1 | THYROID RECEPTOR LIGANDS | TSHR, THRB, THRA | THRB 2/4885THRA 3/4885RORC 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.